Sunday, June 10

SIMULTANEOUS SESSION IV

10:30 - 11:45 hours, Room: Mozart I

MYELOPROLIFERATIVE DISORDERS - CLINICAL

Chairs: T. Barbui (Ospedali Riuniti, Bergamo, Italy)
A. Reiter (University of Heidelberg, Heidelberg, Germany)

10:30 - 10:45
0893

HIGH TROUGHPUT SEQUENOM BASED ASSAY FOR MONITORING JAK2 V617F POST ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO SCT) FOR CLASSIC MYELOPROLIFERATIVE DISORDERS (MPD)
M. Koren-Michowitz, Y. Cohen, A. Shimoni, N. Amariglio, A. Nagler (Chaim Sheba Medical Center, Ramat Gan, Israel)

10:45 - 11:00
0894

JAK2 EXON 12 MUTATIONS OCCUR FREQUENTLY IN IDIOPATHIC ERYTHROCYTOSIS PATIENTS WITH LOW SERUM ERYTHROPOIETIN LEVELS
M.J. Percy, L.M. Scott, W.N. Erber, C.N. Harrison, J.T. Reilly, F.G.C. Jones, A.R. Green, M.F. McMullin (Belfast City Hospital, Belfast, United Kingdom)

11:00 - 11:15
0895

THE IMPACT OF V617F JAK-2 GENE MUTATION ON PLATELET, GRANULOCYTE AND PLASMA HEMOSTATIC AND INFLAMMATORY MOLECULES IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
A. Falanga, M. Marchetti, A. Vignoli, D. Balducci, L. Russo, V. Guerini, T. Barbui (Ospedali Riuniti di Bergamo, Bergamo, Italy)

11:15 - 11:30
0896

HIGHER LEUKOCYTE COUNT IS A RISK FACTOR FOR THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA
E. Antonioli, P. Guglielmelli, A. Tosetto, G. Poli, M. Bernardi, V. Ponziani, F. Rodeghiero, A. Bosi, M. Ruggeri, A.M. Vannucchi (University of Florence, Florence, Italy)

11:30 - 11:45
0897

THE PHENOTYPE OF JAK2V617F MUTANT PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA IS NOT RELATED TO THE BURDEN OF MUTANT ALLELE
E. Antonioli, P. Guglielmelli, G. Poli, G. Longo, V. Ponziani, A. Pancrazzi, A. Bosi, A.M. Vannucchi (University of Florence, Florence, Italy)

SIMULTANEOUS SESSION

10:30 - 11:45 hours, Room: Mozart III

ACUTE MYELOID LEUKEMIA - BIOLOGY II

Chairs: F. Lo Coco (University Tor Vergata, Rome, Italy)
M. Alberich Jorda (Harvard Institute of Medicine, Boston, USA)

10:30 - 10:45
0898

UNRAVELING LEUKAEMOGENIC MECHANISMS AND TARGETS OF NUP98/HOMEO-DOMAIN RECOMBINATIONS IN AML THROUGH A NEW NUP98/HHEX FUSION GENE
J. Schwaller, D. Jankovic, P. Gorello, R. La Starza, C. Desjobert, T. Liu, S. Ehret, P.-S. Jayaraman, C. Mecucci (University Hospital Basel, Basel, Switzerland)

10:45 - 11:00
0899

THE ALTERNATIVELY SPLICED ISOFORM AML1-ETO9A IS DETECTABLE IN ALL T(8;21)-POSITIVE ACUTE MYELOID LEUKEMIAS: CORRELATION OF THE EXPRESSION LEVEL WITH CLINICAL OUTCOME
Ch. Schön, R.F. Schlenk, J. Vehma, K. Eiwen, H. Döhner, K. Döhner (Uniklinikum Ulm, Ulm, Germany)

11:00 - 11:15
0900

CRYPTIC 3Q26 ABERRATIONS PARTLY EXPLAIN ABNORMAL EXPRESSION OF EVI1 IN AML CASES WITHOUT CYTOGENETICALLY RECOGNIZABLE TRANSLOCATIONS IN THIS LOCUS
L. Sanne, E. Van Drunen, H. Beverloo, Y. Van Norden, P.J.M. Valk, B. Lowenberg, H.R. Delwel (Erasmus MC, Rotterdam, The Netherlands)

11:15 - 11:30
0901

THE T(6;9) ASSOCIATED DEK/CAN FUSION PROTEIN DOES NOT BLOCK DIFFERENTIATION OF EARLY HEMATOPOIETIC STEM CELLS BUT INCREASES THEIR SELF RENEWAL POTENTIAL
M. Ruthardt, C. Oancea (Klinikum der J. W. Goethe Universität, Frankfurt, Germany)

11:30 - 11:45
0902

BORN TO BE EXPORTED: C-TERMINUS NUCLEAR EXPORT SIGNALS OF DIFFERENT STRENGTH ENSURE CYTOPLASMIC ACCUMULATION OF NUCLEOPHOSMIN LEUKEMIC MUTANTS
N. Bolli, I. Nicoletti, M.F. De Marco, B. Bigerna, A. Pucciarini, R. Mannucci, M.P. Martelli, B.R. Henderson, B. Falini (Institute of Hematology, Perugia, Italy)

SIMULTANEOUS SESSION

10:30 - 11:45 hours, Room: Strauss I

CHRONIC MYELOID LEUKEMIA - BIOLOGY

Chairs: T. Hughes (Royal Adelaide Hospital, Adelaide, Australia)
J. Melo (Imperial College, London, United Kingdom)

10:30 - 10:45
0903

BMS-214662 TARGETS AN EARLY PROGENITOR POPULATION IN PRIMARY CML AND INDUCES APOPTOSIS IN THE QUIESCENT FRACTION AFTER SENSITIZATION BY THE MEK 1/2 INHIBITOR U0126
F. Pellicano, M. Copland, H. Jorgensen, T. Holyoake (University of Glasgow, Glasgow, United Kingdom)

10:45 - 11:00
0904

THE P-LOOP MUTATIONS Y253H AND E255K/V MAY DEVELOP MORE FREQUENTLY THAN T315I DURING NILOTINIB THERAPY AFTER IMATINIB FAILURE AND ARE ASSOCIATED WITH PROGRESSION IN PATIENTS WITH PH-POSITIVE LEUKEMIA
S. Branford, Y. Shou, R. Lawrence, Z. Rudzki, T. Hughes (Institute of Medical &Veterinary Science, Adelaide, Australia)

11:00 - 11:15
0905

NOVEL PATHWAY IN BCR-ABL SIGNAL TRANSDUCTION INVOLVES AKT-INDEPENDENT ACTIVATION OF PLC-GAMMA/MTOR/P70-S6 KINASE
B. Markova, F. Breitenbuecher, J.V. Melo, J. Duyster, C. Huber, T. Fischer (University Hospital, Mainz, Germany)

11:15 - 11:30
0906

DELETIONS OF THE DERIVATIVE CHROMOSOME 9 DO NOT INFLUENCE RESPONSE TO IMATINIB IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS (A GIMEMA WORKING PARTY ANALYSIS)
F. Castagnetti, F. Palandri, G Marzocchi, S. Luatti, N. Testoni, M. Amabile, S. Soverini, S. Kerim, E. Giugliano, G. Specchia, A. Cuneo, G. Martinelli, G. Alimena, M. Baccarani, G Rosti (Institute of Hematology "Seràgnoli", Bologna, Italy)

11:30 - 11:45
0907

THE INTRACELLULAR CONCENTRATIONS OF IMATINIB AND NILOTINIB, CAN BE SUBSTANTIALLY ALTERED BY INTERACTION WITH OTHER DRUGS: STUDIES WITH PROTON PUMP INHIBITORS
D. White, V.A. Saunders, P. Dang, K. Lynch, P. Manley, T.P. Hughes (IMVS and Hanson Institute, Adelaide, Australia)

SIMULTANEOUS SESSION

10:30 - 11:45 hours, Room: Strauss II

CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - BIOLOGY

Chairs: M. Ferrarini (National Institute for Cancer Research, Genoa, Italy)
S. Stilgenbauer (University of Ulm, Ulm, Germany)

10:30 - 10:45
0908

EXPRESSION LEVELS OF CLLU1 AND LPL : NEW DISEASEASSESSMENT TOOLS IN CLL PATIENTS IN BINET STAGE A ?
S. Hayette, S. Hayette, C. Bastard, M.J. Mozziconacci, C. Messana, C. Charlot, C. Locher, M. Gadoux, L. Baseggio, M. Ticchioni, B. Lenormand, G. Salles, C. Arnoulet, J.P. Magaud, E. Callet-Bauchu, S. Raynaud (Centre Hospitalier Lyon Sud, Pierre-Benite, France)

10:45 - 11:00
0909

QUANTITATIVE GENE EXPRESSION ANALYSIS OF SURROGATE MARKERS FOR GENETIC RISK GROUPS AND SURVIVAL IN CLL
D.K. Kienle, A. Benner, C.S. Schneider, D.W. Winkler, A.H. Habermann, M.H. Hensel, P. Lichter, R.D. Dalla-Favera, H. Döhner, S. Stilgenbauer (University of Ulm, Ulm, Germany)

11:00 - 11:15
0910

FUNCTIONAL IMPAIRMENT OF THE P53 PATHWAY DETECTED BY FLOW CYTOMETRY IS A NOVEL INDEPENDENT ADVERSE PROGNOSTIC FACTOR IN CHRONIC LYMPHOCYTIC LEUKAEMIA
A.R. Pettitt, A Carter, K. Lenehan, K. Lin (University of Liverpool, Liverpool, United Kingdom)

11:15 - 11:30
0911

THE ANTITUMOR ACTIVITY OF LUMILIXIMAB IS MEDIATED THROUGH THE INDUCTION OF CASPASE-9–DEPENDENT APOPTOSIS AND IS SYNERGISTIC WITH RITUXIMAB AND FLUDARABINE IN CD23+ CLL AND LYMPHOMA CELLS
N. Pathan, J.C. Byrd, K. Hariharan, P. Chu, A. Molina (Biogen Idec, San Diego, USA)

11:30 - 11:45
0912

IN VITRO MODEL FOR LYMPHOID MICROENVIRONMENT AND INHIBITION OF APOPTOSIS IN B-CLL CELLS: INVOLVEMENT OF PI3-K/AKT PATHWAY AND PTEN
M. Shehata, S. Schnabl, D. Demirtas, J.D. Schwarzmeier, M. Hilgarth, M. Duechler, A. Gaiger, R. Hubmann, U. Jaeger (Medical University of Vienna, Vienna, Austria)

SIMULTANEOUS SESSION

10:30 - 11:45 hours, Room: Strauss III

RED CELLS AND IRON

Chairs: P. Beris (Geneva University Hospital, Geneva, Switzerland)
W. van Solinge (University Medical Center Utrecht, Utrecht, The Netherlands)

10:30 - 10:45
0913

PLASMA LIPOCALIN-2 LEVELS IN PATIENTS WITH THALASSEMIA INTERMEDIA: CORRELATION WITH IRON METABOLISM AND ERYTHROPOIESIS
I. Papassotiriou, A. Margeli, V. Ladis, S. Sophia, K. Kassiou, A. Kattamis (Aghia Sophia Children's Hospital, Athens, Greece)

10:45 - 11:00
0914

ZOLEDRONIC ACID INCREASES BONE MINERAL DENSITY IN PATIENTS WITH THALASSEMIA INTERMEDIA-INDUCED OSTEOPOROSIS DESPITE THE CONTINUOUS BONE MARROW EXPANSION
E. Voskaridou, D. Christoulas, L. Antoniadou, P. Tsaftaridis, E. Plata, E. Terpos (Thalassemia Center, Laikon General Hosp., Athens, Greece)

11:00 - 11:15
0915

PROTEOMIC AND BIOCHEMICAL PROFILING OF 4.1R DEFICIENT RED BLOOD CELLS
K. Jeremy, Z. Plummer, D. Head, J. Delaunay, N. Avent (University of the West of England, Bristol, United Kingdom)

11:15 - 11:30
0916

INHIBITION OF INCREASED SICKLE NEUTROPHIL ADHESION TO ICAM-1 BY NITRIC OXIDE DONORS AND ACTIVATION OF CGMP SIGNALING
A. Canalli, N. Conran, S.T.O. Saad, F.F. Costa (Unicamp, Campinas, Brazil)

11:30 - 11:45
0917

USEFULNESS OF THE EOSIN-5’-MALEIMIDE CYTOMETRIC METHOD AS A FIRST-LINE SCREENING TEST FOR THE DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS: COMPARISON WITH EKTACYTOMETRY AND PROTEIN ELECTROPHORESIS
F. Girodon, L. Garçon, M. Largier, E. Bergoin, J. Delaunay, M. Thibaut, M. Maynadié, T. Cynober (CHU Bocage, Dijon, France)

SIMULTANEOUS SESSION

10:30 - 11:45 hours, Room: Léhar I+II

NON-HODGKIN'S LYMPHOMA - BIOLOGY

Chairs: A. Rosenwald (University of Würzburg, Würzburg, Germany)
G. Salles (Centre Hospitaire Lyon-Sud, Lyon, France)

10:30 - 10:45
0918

JUNCTIONAL ADHESION MOLECULE C (JAM-C) DIFFERENTIATES CD27 POSITIVE B LYMPHOCYTES INTO GERMINAL CENTER AND NON-GERMINAL CENTER CELLS AND CONSTITUTES A NEW DIAGNOSTIC MARKER FOR B CELL MALIGNANCIES
Th. Matthes, C. Ody, S. Jungblut-Ruault, D. Cossali, M. Barnet, M. Aurrand-Lions, B. Imhof (University Hospital Geneva, Geneva, Switzerland)

10:45 - 11:00

0919

ROLE OF JUNB IN ALCL LYMPHOMA DEVELOPMENT
D. Laimer, P. Vesely, P. Staber, P. Pflegerl, R. Brandes, M. Schlederer, G. Hoefler, L. Kenner (Medical University Vienna, Vienna, Austria)

11:00 - 11:15
0920

THE ONCOPROTEIN NPM-ALK INDUCES TRANSLATION OF AP-1 FACTORS VIA MTOR SIGNALLING
P. Staber, P. Vesely, C. Fuchs, I. Bambach, S. Schauer, H. Bergler, D. Sternberg, G. Hoefler (Medical University Graz, Graz, Austria)

11:15 - 11:30
0921

ANALYSIS OF MICRORNAS EXPRESSION PATTERN IN CLASSICAL HODGKIN LYMPHOMA
A. Navarro, A. Gaya, A. Urbano-Ispizua, A. Pons, A. Martinez, B. Gel, O. Balague, P. Abrisqueta, A. Lopez-Guillermo, R. Artells, E. Montserrat, M. Monzo (University of Barcelona, Barcelona, Spain)

11:30 - 11:45
0922

FREQUENT CRYPTIC ALTERATIONS DETECTED BY SNP-CHIPS IN BURKITT LYMPHOMAS
V. Havelange, E. Callet-Bauchu, I. Theate, F. Mugneret, L. Michaux, C. Barin, N. Dastugue, E. Lippert, P. Saussoy, D. Penther, M. Vikkula, H. Poirel (Cliniques Universitaires Saint-Luc, Brussels, Belgium)

SIMULTANEOUS SESSION

10:30 - 11:45 hours, Room: Léhar III+IV

CYTOGENETICS, MOLECULAR DIAGNOSTICS AND TARGETED THERAPIES

Chairs: B. Schlegelberger (Hanover Medical School, Hanover, Germany)
C. Chomienne (Institute Universitaire d’Hematologie, Paris, France)

10:30 - 10:45
0923

HIGH RESPONSE RATE AFTER SEQUENTIAL ADMINISTRATION OF AZACITIDINE, VALPROIC ACID, AND ATRA IN PREVIOUSLY UNTREATED OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
E. Raffoux, C. Recher, N. Boissel, R. Oumedaly, I. Lobe, F. Huguet, D. Rea, P. Chaibi, A. De Labarthe, P. Fenaux, L. Degos, C. Gardin, H. Dombret (Hopital Saint Louis, Paris, France)

10:45 - 11:00
0924

TARGETING ICMT AMELIORATES K-RAS-INDUCED MYELOPROLIFERATIVE DISEASE AND LUNG CANCER
M. Bergo, A.M. Wahlstrom, M. Liu, C. Karlsson, B. Swolin, B.A. Cutts (Sahlgrenska University Hospital, Goteborg, Sweden)

11:00 - 11:15
0925

PROGNOSTIC IMPACT OF CHROMOSOMAL ABNORMALITIES IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA TREATED WITH HIGH-DOSE MELPHALAN (MEL140) AND AUTOLOGOUS STEM CELL TRANSPLANTATION
P. Liebisch, C. Straka, A. Wimmer, C. Wendl, A. Hinke, S. Ibach, H. Döhner (University Hospital of Ulm, Ulm, Germany)

11:15 - 11:30
0926

A NEW APPROACH TO MRD MONITORING IN AML, REAL-TIME QUANTIFICATION OF MULTIPLE AML-UPREGULATED GENES
K. Tobal, G.J. Mufti (King's College Hospital, London, United Kingdom)

11:30 - 11:45
0927

MK-0457, A NOVEL MULTIKINASE INHIBITOR, IS ACTIVE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AND ACUTE LYMPHOCYTIC LEUKEMIA (ALL) WITH THE T315I BCRABL RESISTANCE MUTATION AND PATIENTS WITH REFRACTORY JAK-2 POSITIVE MYELOPROLIFERATIVE DISEASES (MPD)
J. Giles, J. Cortes, D.A. Bergstrom, A. Xiao, D. Jones, S. Verstovsek, D. Thomas, D. Rizzieri, S.J. Freedman, H. Kantarjian (M.D. Anderson Cancer Center, Houston, USA)

SIMULTANEOUS SESSION

10:30 - 11:45 hours, Room: Stolz I

EPIGENETICS, TRANSCRIPTION AND SIGNALLING

Chairs: G. de Haan (University Medical Center, Groningen, The Netherlands)
K. Podar (Dana-Farber Cancer Institute, Boston, USA)

10:30 - 10:45
0928

TRANSCRIPTIONAL REGULATION OF HEMO-OXIGANASE-1 AND A SECRETED PROTEIN ACIDIC AND RICH IN CYSTEINE (SPARC) IN BORTEZOMIB-TREATED ADULT T-CELL LEUKEMIA CELLS
H. Ryoko, J.H. Ohyashiki, C. Kobayashi, A. Hirota, Y. Zhang, T. Takaku, K. Ohyashiki (Tokyo Medical University, Tokyo, Japan)

10:45 - 11:00
0929

LACK OF MHC-II MOLECULE EXPRESSION IN T-LEUKAEMIA IS ASSOCIATED WITH DISTINCT EPIGENETIC DNA AND HISTONE MODIFICATIONS AT PROMOTER III CHROMATIN OF MHC2TA
P.J. van den Elsen, T.M. Holling, M.C.J.A. Van Eggermond (Leiden University Medical Center, Leiden, The Netherlands)

11:00 - 11:15
0930

UNCOVERING THE EPIGENETIC PATHOMECHANISM IN 13Q14
D. Mertens, M. Ruppel, A. Philippen, C. Tschuch, V. Fleig, C. Mund, F. Lyko, B. Radlwimmer, H. Döhner, S. Stilgenbauer, P. Lichter (University Hospital Ulm, DKFZ Heidelberg, Ulm, Germany)

11:15 - 11:30
0931

BETA-TRCP MEDIATES UBIQUITINATION AND DEGRADATION OF THE ERYTHROPOIETIN RECEPTOR AND CONTROLS CELL PROLIFERATION
F. Verdier, L. Meyer, B. Deau, H. Forejtnikova, D. Dumenil, F. Margottin-Goguet, C. Lacombe, P. Mayeux (Cochin Institute, Paris, France)

11:30 - 11:45
0932

IDENTIFICATION OF PROTEIN TYROSINE KINASES THAT CAN SUPPORT THE PROLIFERATION AND SURVIVAL OF HEMATOPOIETIC CELLS
E. Lierman (K.U. Leuven, Leuven, Belgium)

[ Top of page ]